Ropivacaine
Naropin (ropivacaine) is a small molecule pharmaceutical. Ropivacaine was first approved as Naropin on 1996-09-24. It is used to treat postoperative pain in the USA. It is known to target sodium channel protein type 5 subunit alpha.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
---|---|
signs and symptoms pathological conditions | D013568 |
Trade Name
FDA
EMA
Naropin (generic drugs available since 2014-07-17)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Ropivacaine hydrochloride
Tradename | Company | Number | Date | Products |
---|---|---|---|---|
NAROPIN | Fresenius Kabi | N-020533 RX | 1996-09-24 | 11 products, RLD, RS |
Show 1 discontinued
Labels
FDA
EMA
Brand Name | Status | Last Update |
---|---|---|
naropin | New Drug Application | 2022-12-29 |
ropivacaine hydrochloride | ANDA | 2023-03-23 |
Agency Specific
FDA
EMA
No data
HCPCS
Code | Description |
---|---|
J2795 | Injection, ropivacaine hydrochloride, 1 mg |
Clinical
Clinical Trials
10 clinical trials
View more details
![](https://www.pharmakb.com/hubfs/raw_assets/public/ccd-theme/images/generated-html-images/trials-plot.png)
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Vomiting | D014839 | HP_0002013 | R11.1 | 3 | 1 | 3 | — | — | 7 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Germ cell and embryonal neoplasms | D009373 | — | 1 | — | — | — | 1 | ||
Postoperative nausea and vomiting | D020250 | EFO_0004888 | — | 1 | — | — | — | 1 |
Indications Phases 1
No data
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common name | ROPIVACAINE |
INN | ropivacaine |
Description | (S)-ropivacaine is a piperidinecarboxamide-based amide-type local anaesthetic (amide caine) in which (S)-N-propylpipecolic acid and 2,6-dimethylaniline are combined to form the amide bond. It has a role as a local anaesthetic. It is a piperidinecarboxamide and a ropivacaine. |
Classification | Small molecule |
Drug class | local anesthetics |
Image (chem structure or protein) | |
Structure (InChI/SMILES or Protein Sequence) | CCCN1CCCC[C@H]1C(=O)Nc1c(C)cccc1C |
Identifiers
PDB | — |
CAS-ID | 84057-95-4 |
RxCUI | 35780 |
ChEMBL ID | CHEMBL1077896 |
ChEBI ID | 8890 |
PubChem CID | 175805 |
DrugBank | DB00296 |
UNII ID | 7IO5LYA57N (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
SCN5A
SCN5A
Organism
Homo sapiens
Gene name
SCN5A
Gene synonyms
NCBI Gene ID
Protein name
sodium channel protein type 5 subunit alpha
Protein synonyms
cardiac tetrodotoxin-insensitive voltage-dependent sodium channel alpha subunit, hH1, Sodium channel protein cardiac muscle subunit alpha, Sodium channel protein type V subunit alpha, sodium channel, voltage-gated, type V, alpha subunit, Voltage-gated sodium channel subunit alpha Nav1.5
Uniprot ID
Mouse ortholog
Scn5a (20271)
sodium channel protein type 5 subunit alpha (Q9JJV9)
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
![](https://www.pharmakb.com/hubfs/raw_assets/public/ccd-theme/images/generated-html-images/top-terms-plot.png)
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 9,811 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
![](https://www.pharmakb.com/hubfs/raw_assets/public/ccd-theme/images/generated-html-images/top-adverse-reactions-plot.png)
Mock data
Subscribe for the real data
Subscribe for the real data
889 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more